| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 09/30/2004 | WO2004083428A1 In vitro cloning methods |
| 09/30/2004 | WO2004083427A2 Ligational encoding of small molecules |
| 09/30/2004 | WO2004083426A1 Novel antisense oligonucleotide and anti-hiv agent |
| 09/30/2004 | WO2004083423A1 Thermally stable amidases |
| 09/30/2004 | WO2004083419A1 Fructosylamine oxidase |
| 09/30/2004 | WO2004083418A1 Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
| 09/30/2004 | WO2004083417A1 The transformed plant cell expressing tandem repeats of beta-amyloid gene and plant produced by the same |
| 09/30/2004 | WO2004083414A1 Monocyte-origin multipotent cell momc |
| 09/30/2004 | WO2004083402A2 Spleen necrosis predictive genes |
| 09/30/2004 | WO2004083398A2 Therapeutic uses of hmgn1 and hmgn2 |
| 09/30/2004 | WO2004083394A2 Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders |
| 09/30/2004 | WO2004083391A2 Targeted and regional cellular ablation in zebrafish |
| 09/30/2004 | WO2004083388A2 Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| 09/30/2004 | WO2004083378A2 Mammalian cell lines specifically deficient in o-linked glycosylation |
| 09/30/2004 | WO2004083373A2 Antibody against the g glycoprotein of respiraotry syncytial virus |
| 09/30/2004 | WO2004083365A2 Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs |
| 09/30/2004 | WO2004083362A2 Modification of subtilases using protein modelling based on the jp170 three-dimensional structure |
| 09/30/2004 | WO2004083361A2 FVII OR FVIIa VARIANTS |
| 09/30/2004 | WO2004083248A1 Antibodies to igf-i receptor for the treatment of cancers |
| 09/30/2004 | WO2004083247A1 Humanized anti-cd4 antibody with immunosuppressive properties |
| 09/30/2004 | WO2004083245A2 Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
| 09/30/2004 | WO2004083240A2 Regulation of gene expression |
| 09/30/2004 | WO2004083175A2 Methods for identifying enzyme inhibitors and protein kinases |
| 09/30/2004 | WO2004082720A1 Drug for treating hemophilia and method of treating hemophilia using the same |
| 09/30/2004 | WO2004082690A1 Regulation of cell surface proteins |
| 09/30/2004 | WO2004082598A2 Relaxin3-gpcr135 complexes and their production and use |
| 09/30/2004 | WO2004082517A2 Animal exhibiting ptsd-like behavior, per pct rule 4.3 |
| 09/30/2004 | WO2004082399A2 Fish and the production thereof |
| 09/30/2004 | WO2004082374A1 Model for muscular dystrophy and cardiomyopathy |
| 09/30/2004 | WO2004082370A2 Cardiac-preferred genetic alteration of transgenic rabbits |
| 09/30/2004 | WO2004082369A1 Reduced stature plants |
| 09/30/2004 | WO2004082368A2 Improved plant transformation |
| 09/30/2004 | WO2004082366A2 Methods to confer enhanced floral properties to plants |
| 09/30/2004 | WO2004074501A3 A method for obtaining structural information about an encoded molecule |
| 09/30/2004 | WO2004074445A9 Model for studying the role of genes in tumor resistance to chemotherapy |
| 09/30/2004 | WO2004074429A3 Method for producing second-generation library |
| 09/30/2004 | WO2004073603A3 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/30/2004 | WO2004072221A3 Proteases |
| 09/30/2004 | WO2004065596A3 Use of the regulatory sequence of the rice gos2 gene for the gene expression in dicotyledonous plants or plant cells |
| 09/30/2004 | WO2004064768A3 Animal model for alzheimer's disease |
| 09/30/2004 | WO2004060408A8 p53 TREATMENT OF PAPILLOMAVIRUS AND CARCINOGEN-TRANSFORMED CELLS IN HYPERPLASTIC LESIONS |
| 09/30/2004 | WO2004056850A3 Mutant proteins showing increased secretion |
| 09/30/2004 | WO2004055211A3 Compositions and methods for detecting and treating neurodegenerative pathologies |
| 09/30/2004 | WO2004053083A3 Modulation of fetoprotein transcription factor expression |
| 09/30/2004 | WO2004053053A3 Optimised protein synthesis |
| 09/30/2004 | WO2004052306A3 Modulation of ppar-alpha expression |
| 09/30/2004 | WO2004046355A3 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof |
| 09/30/2004 | WO2004045544A3 Autocrine growth factor receptor antibodies and methods |
| 09/30/2004 | WO2004044157A3 Gp64-pseudotyped vectors and uses thereof |
| 09/30/2004 | WO2004044004A3 T cell receptor display |
| 09/30/2004 | WO2004042046A3 Effective and stable dna enzymes |
| 09/30/2004 | WO2004039957A3 Inhibition of gene expression using rna interfering agents |
| 09/30/2004 | WO2004037982A3 High expression locus vector based on ferritin heavy chain gene locus |
| 09/30/2004 | WO2004037194A3 Novel compositions with chitinase activity |
| 09/30/2004 | WO2004035819A8 Oligonucleotide analogues for detecting and analyzing nucleic acids |
| 09/30/2004 | WO2004029070A3 Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors |
| 09/30/2004 | WO2004018621A3 Method for determining gene knockout strategies |
| 09/30/2004 | WO2004017910A3 Total synthesis of heparin |
| 09/30/2004 | WO2004013336A3 Use of pox4 promoter to increase gene expression in candida tropicalis |
| 09/30/2004 | WO2004011613A3 Composition & methods for treatment and screening |
| 09/30/2004 | WO2004011610A3 Antisense modulation of polo-like kinase expression |
| 09/30/2004 | WO2004007663A3 Gene expression using metal ion dependent repressor/operator tandems |
| 09/30/2004 | WO2003106972A3 Multiple domain tdf-related compounds and analogs thereof |
| 09/30/2004 | WO2003103586A3 Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| 09/30/2004 | WO2003099860A3 Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition |
| 09/30/2004 | WO2003083055A3 Hybridization rate enhancement for substrate-bound specific nucleic acid-binding agents |
| 09/30/2004 | WO2003082200A3 Potent oncolytic herpes simplex virus for cancer therapy |
| 09/30/2004 | WO2003080105A9 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 09/30/2004 | WO2003072740A3 Novel type-1 cytokine receptor glm-r |
| 09/30/2004 | WO2003062447A3 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 09/30/2004 | WO2003054016A8 Method for cloning of variable domain sequences |
| 09/30/2004 | WO2003052065A3 Antisense modulation of b-cell associated protein expression |
| 09/30/2004 | WO2003049703A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 09/30/2004 | WO2003048328A9 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 09/30/2004 | WO2003046152A3 Molecules for disease detection and treatment |
| 09/30/2004 | WO2003046126A3 Artificial genes for use as controls in gene expression analysis systems |
| 09/30/2004 | WO2003039491A3 Novel isoforms of vascular endothelial cell growth inhibitor |
| 09/30/2004 | WO2003031930A3 A phosphatase associated with metastasis |
| 09/30/2004 | WO2003016503A3 Genes encoding carotenoid compounds |
| 09/30/2004 | WO2003014323A3 Human smooth muscle myosin heavy chain |
| 09/30/2004 | US20040194166 Transgenic tobacco plant comprising nucleotide sequences coding thyroid-stimulating hormone or gonadotrophin-receptor for use in treatment of reproductive disorders; bioreactors and therapeutic polypeptides |
| 09/30/2004 | US20040194165 Expression vector coding insecticidal protein for use in the transformation and generation of moth resistant leafy plants |
| 09/30/2004 | US20040194164 Xenorhabdus TC proteins and genes for pest control |
| 09/30/2004 | US20040194163 GTP binding stress-related proteins and methods of use in plants |
| 09/30/2004 | US20040194162 Manipulation of genes of the mevalonate and isoprenoid pathways to create novel traits in transgenic organisms |
| 09/30/2004 | US20040194161 Methods of transforming plants and identifying parental origin of a chromosome in those plants |
| 09/30/2004 | US20040194159 Cloning pigs using donor nuclei from differentiated cells |
| 09/30/2004 | US20040194155 Comprises hepatitis b viral nucleotide sequences coding mutant reverse transcriptase for use in developing antibodies to prevent or treat hepatitis viral infection; immunotherapy; |
| 09/30/2004 | US20040193921 Systems and methods for authenticating a user to a web server |
| 09/30/2004 | US20040193111 Targeting gene expression to living tissue using jet injection |
| 09/30/2004 | US20040192903 Comprises chromosomal regoin which codes pathogenicity islands (PAIs) for use in developing antibodies to detect and prevent bacterial infection; bactericides |
| 09/30/2004 | US20040192899 B-7 domain-specific antibodies |
| 09/30/2004 | US20040192898 Anti-abeta antibodies |
| 09/30/2004 | US20040192893 comprises cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes for use in labeling nucleic acids or proteins in assay, and as diagnostic aid in genomics/proteomics |
| 09/30/2004 | US20040192892 Isolated mammalian membrane protein genes; related reagents |
| 09/30/2004 | US20040192891 Mammalian cytokines; related reagents and methods |
| 09/30/2004 | US20040192886 for use in the treatment and prevention of nervous system, epileptic, pain and vision defects; neuromuscular blocking agents; local anesthetic ; analgesics; neuroprotective agents |
| 09/30/2004 | US20040192776 Cationic lipid compositions targeting angiogenic endothelial cells |
| 09/30/2004 | US20040192633 Antisense modulation of short heterodimer partner-1 expression |
| 09/30/2004 | US20040192632 comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with the Non-Immunogenic or High Molecular Weight Compound |